18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
2 citations
,
October 1999 in “The Journal of Urology”
June 2018 in “International Review of Intellectual Property and Competition Law” Finasteride helps treat male hair loss but may lower sex drive.
6 citations
,
December 2019 in “Dermatologic Therapy” Oral dutasteride improves hair growth, reduces hair loss, and is safe for most patients.
1 citations
,
November 2016 in “Journal of the Dermatology Nurses’ Association” Finasteride treats hair loss but may cause side effects like low libido and dizziness.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
125 citations
,
January 1999 in “Drugs” Finasteride effectively treats baldness but may cause sexual side effects.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
January 2023 in “Marmara University Open Access System” Tideglusib with hydrogel improves wound healing in rats.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
November 2005 in “The Journal of Urology”
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
January 2011 in “Reactions Weekly” May 2007 in “Inpharma Weekly”
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
January 2017 in “Clinical pharmacist” Long use of finasteride and dutasteride can cause long-term erection problems.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
2 citations
,
February 2020 in “Rivista Urologia” Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.
September 2024 in “Dermatology” Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.